This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* Advances in ADP Receptor Blockade in ACS
* Case
* Clopidogrel in NSTE ACS: CURE
* Clopidogrel Efficacy Across NSTE ACS Risk Spectrum
* CURE: Efficacy of Very Early Clopidogrel in NSTE ACS
* Clopidogrel in STEMI
* CLARITY-TIMI 28: 1 Endpoint
* COMMIT
* PCI-CLARITY Design
* Clopidogrel Pretreatment
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
The guest, Marc Sabatine, MD, has nothing to disclose regarding this CME activity.
|
|